confirming the reduction of both NF-κB methylation and its subsequent activation upon drug treatment. These findings provide compelling grounds for considering Can and Clo as anti-PRMT5 cancer ...

Previous research from the Adli laboratory showed an abundance of PRMT5—an enzyme known for its role in regulating gene expression—in chemotherapy-resistant ovarian cancer. In the current ...

TNG908, an MTA-cooperative brain penetrant PRMT5 inhibitor, is clinically active and well-tolerated in non-CNS solid tumors including NSCLC and pancreatic cancer. However, TNG908 did not meet the ...

Previous research has shown that selective inhibition of protein arginine methyltransferase 5 (PRMT5) in the presence of MTA may be considered a potential therapeutic strategy for the treatment of ...

Shares in Tango fell 26% to $3.81 in premarket trading. TNG908 is a MTA-cooperative PRMT5 inhibitor. In cells with MTAP deletion, a mutation found in 10% to 15% of solid tumors, the metabolite MTA ...

Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...

An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor ...